Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Dysregulation of hepcidin, a key iron regulating hormone, is important in the pathogenesis of iron overload in patients with myelodysplatic syndrome (MDS). However, most studies of hepcidin levels are complicated by concomitant RBC transfusions. To evaluate the relationship between iron metabolism and erythropoiesis, we measured serum levels of hepcidin, growth-differentiation factor-15 (GDF15) and other markers of erythropoiesis in 107 subjects with MDS not receiving RBC transfusions. Patients with MDS had significantly higher levels of hepcidin than normals. However, their hepcidin–ferritin ratio was markedly decreased compared to normals (P < 0.001) and varied substantially between MDS subtypes (P = 0.011). GDF15 levels positively correlated with percent of bone marrow erythroblasts (P < 0.001), soluble transferrin receptor (sTfR) (P = 0.018), and also with transferrin saturation (ISAT) (P = 0.038). The hepcidin–ferritin ratio negatively correlated with serum erythropoietin (EPO) levels (P < 0.001), and also with GDF15 levels (P = 0.014). Colony forming cells (CFC) were evaluated in 70 subjects. Those with serum ferritin (SF) levels <500 ng/ml had significantly more BFU-E than subjects with SF≥ 500 ng/L (P = 0.007), but numbers of granulocyte/macrophage-colony-forming cells (CFU-GM) were similar (P = 0.190). Our data indicate serum hepcidin levels are inappropriately low in patients MDS not receiving RBC transfusions. GDF15 levels correlated with low hepcidin levels and may contribute to iron overload in this setting. Iron overload may in turn suppress erythropoiesis by imparing the proliferative capacity of the erythroid progenitor cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427 · cited 4×
“SF < 500 ng/ml (N = 43) SF ≥ 500 ng/ml (N = 27) P Sex (Male) 16 21 0.001 Age (year) 48 (24–84) 50 (19–79) 0.350 WHO MDS subtypes (N) 0.431 5q-Syndrome 1 0 RA/-RS 6 3 RCMD/-RS 23 11 RAEBI/II 13 12 Unclassified 0 1 IPSS (N) 0.221 Low 4 1 Int-1 27 13 Int-2 8 11 High 1 1 No data 3 1 IPSS cytogenetics (N) 0.259 Low 27 13 I…”
MethodInfluentialNicolas, G., Chauvet, C., Viatte, L., Danan, J. L., Bigard, X., Devaux, I., Beaumont, C., Kahn, A., & Vaulont, S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215686 · Cited by 1,214 · cited 1×
“Although giving EPO to mice results in down-regulation of hepcidin and increased iron absorption [22], hepcidin expression is not suppressed when erythropoiesis is inhibited pharmacologically.”
BackgroundHigh levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin
Tanno, T., Bhanu, N. V., Oneal, P. A., Goh, S.-H., Staker, P., Lee, Y. T., Moroney, J. W., Reed, C. H., Luban, N. L., Wang, R.-H., et al. (2007) · Nature Medicine · doi:10.1038/nm1629 · Cited by 854 · cited 4×
“GDF15 has been identified as a negative regulator of hepcidin expression in patients with βthalassaemia and in isolated human hepatocytes [7].”
BackgroundInfluentialHepcidin and disorders of iron metabolism
Ganz, T., & Nemeth, E. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-050109-142444 · Cited by 466 · cited 1×
“Iron excess stimulates hepcidin production, whereas iron deficiency and increased erythropoiesis suppresses hepcidin production [6].”
BackgroundTanno, T., Porayette, P., Sripichai, O., Noh, S.-J., Byrnes, C., Bhupatiraju, A., Lee, Y. T., Goodnough, J. B., Harandi, O., Ganz, T., et al. (2009) · Blood · doi:10.1182/blood-2008-12-195503 · Cited by 352
Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis
Liu, Q., Davidoff, O., Niss, K., & Haase, V. H. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63924 · Cited by 328 · cited 4×
“A hypothesis that could explain the the relationship between iron metabolism and erythropoiesis in patients with MDS not receiving RBC transfusions is that tissue hypoxia triggers EPO production, which increases erythropoiesis accompanied by increased serum GDF15 levels [23].”
BackgroundResultInfluentialTamary, H., Shalev, H., Perez-Avraham, G., Zoldan, M., Levi, I., Swinkels, D. W., Tanno, T., & Miller, J. L. (2008) · Blood · doi:10.1182/blood-2008-06-165738 · Cited by 135 · cited 1×
“A similar increase has already been reported in patients with ineffective erythropoiesis such as β-thalassemia, CDA Iand CDA II [7,9,10].”
BackgroundRamirez, J., Schaad, O., Durual, S., Cossali, D., Docquier, M., Beris, P., Descombes, P., & Matthes, T. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07441.x · Cited by 96 · cited 6×
“2D), with the highest levels in subjects with RARS and the lowest levels in the refractory anemia with excess blasts (RAEB) and refractory cytopenia with multilineage dysplasia (RCMD) cohorts.”
BackgroundInfluentialRegulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency
Finkenstedt, A., Bianchi, P., Theurl, I., Vogel, W., Witcher, D. R., Wroblewski, V. J., Murphy, A. T., Zanella, A., & Zoller, H. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07535.x · Cited by 51
Cited by
Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders
Yatsuga, S., Fujita, Y., Ishii, A., Fukumoto, Y., Arahata, H., Kakuma, T., Kojima, T., Ito, M., Tanaka, M., Saiki, R., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24506 · Cited by 293
A variant erythroferrone disrupts iron homeostasis in SF3B1 -mutated myelodysplastic syndrome
Bondu, S., Alary, A.-S., Lefèvre, C., Houy, A., Jung, G., Lefebvre, T., Rombaut, D., Boussaid, I., Bousta, A., Guillonneau, F., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav5467 · Cited by 85
Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes
de Swart, L., Reiniers, C., Bagguley, T., van Marrewijk, C., Bowen, D., Hellström-Lindberg, E., Tatic, A., Symeonidis, A., Huls, G., Cermak, J., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.171884 · Cited by 48
“An earlier study in 107 untransfused patients observed generally elevated hepcidin levels in MDS, but low hepcidin/ferritin ratios in the RS subtypes, compatible with the low hepcidin levels in the RS patients of our study.(39) In addition, RS patients showed elevated sTFR levels and decreased hepcidin levels compared…”
Result
Metadata
- Authors
- Cui, R., Gale, R. P., Zhu, G., Xu, Z., Qin, T., Zhang, Y., Huang, G., Li, B., Fang, L., Zhang, H., Pan, L., Hu, N., Qu, S., & Xiao, Z.
- Venue
- Leukemia Research
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 38
- Issue
- 5
- Pages
- 545-550
- ISSN
- 0145-2126 (ISSN-L)
- OpenAlex
- W2118046222
- Cited by
- 51
- References
- 9
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.